Loading Events

« All Webinars

“Assessment of Infants With NAS” (Part 1 of 2)

As part of its Neonatal Education Series 2018, Saxe Communications and Philips Healthcare present a  Neonatal Abstinence Syndrome (NAS) Webinars Series

“Assessment of Infants With NAS” (Part 1 of 2)

Drug use among pregnant women can lead to problems in the developing fetus including congenital anomalies, problems with growth, preterm labor, withdrawal or toxicity in the newborn, and later problems with neurodevelopment. One of the most readily apparent problems created by in utero exposure to drugs is neonatal abstinence syndrome. This presentation will discuss the definition of NAS, the drugs that may cause signs of neonatal abstinence, screening methods and the use of the Finnegan scoring tool to assess the severity of withdrawal signs and the importance of being reliable when scoring.

Learning Objectives

After the completion of this activity, the participant will be able to:

  1. Define neonatal abstinence syndrome.
  2. Identify the incidence and hospital costs of infants with NAS.
  3. Describe the Finnegan scoring tool and how it is used to assess infants with NAS


Karen D’Apolito, PhD, NNP-BC, FAAN  l   Director, Neonatal NP Specialty  l  Vanderbilt University School of Nursing

Continuing Education for Nurses: This education activity is approved for 1.0 contact hour. Saxe Healthcare Communications is accredited as a provider for continuing education by the California Board of Nursing Provider #14477 and the Florida Board of Nursing Provider # 50-17032.

Educational support has been provided by Philips Healthcare.

See also program on May 2, 2018: 

“Management of Infants with NAS, Therapeutic Interventions” (Part 2 of 2)

Wed., May 2, 2018, 11AM – 12PM (Central)